{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting&page=26",
    "query": {
      "intervention": "Fasting",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 2245,
    "total_pages": 225,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T15:50:06.161Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02726490",
      "title": "Glyburide vs Glucovance in the Treatment of GDM",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Gestational Diabetes"
      ],
      "interventions": [
        {
          "name": "Glyburide",
          "type": "DRUG"
        },
        {
          "name": "Glucovance",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Texas Tech University Health Sciences Center, El Paso",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2016-07",
      "completion_date": "2018-08-14",
      "has_results": false,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-10-19T15:50:06.161Z",
      "location_count": 1,
      "location_summary": "El Paso, Texas",
      "locations": [
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02726490"
    },
    {
      "nct_id": "NCT04526197",
      "title": "Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Wilson Disease"
      ],
      "interventions": [
        {
          "name": "ALXN1840",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2020-07-07",
      "completion_date": "2020-11-03",
      "has_results": true,
      "last_update_posted_date": "2023-08-21",
      "last_synced_at": "2026-10-19T15:50:06.161Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04526197"
    },
    {
      "nct_id": "NCT02447458",
      "title": "MLN3126 Single Rising Dose Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "MLN3126",
          "type": "DRUG"
        },
        {
          "name": "MLN3126 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 39,
      "start_date": "2013-09",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2015-08-05",
      "last_synced_at": "2026-10-19T15:50:06.161Z",
      "location_count": 1,
      "location_summary": "Eatontown, New Jersey",
      "locations": [
        {
          "city": "Eatontown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02447458"
    },
    {
      "nct_id": "NCT00033150",
      "title": "A Comparison of Language Intervention Programs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Language Disorders"
      ],
      "interventions": [
        {
          "name": "Fast ForWord",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Computer Assisted Language Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Individual Language Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Academic enrichment",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Institute on Deafness and Other Communication Disorders (NIDCD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "9 Years",
        "sex": "ALL",
        "summary": "6 Years to 9 Years"
      },
      "enrollment_count": 216,
      "start_date": "2002-06",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2006-04-24",
      "last_synced_at": "2026-10-19T15:50:06.161Z",
      "location_count": 2,
      "location_summary": "Lawrence, Kansas • Pflugerville, Texas",
      "locations": [
        {
          "city": "Lawrence",
          "state": "Kansas"
        },
        {
          "city": "Pflugerville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00033150"
    },
    {
      "nct_id": "NCT01021020",
      "title": "Bioequivalence Study of Colchicine Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Colchicine",
          "type": "DRUG"
        },
        {
          "name": "Colchicine/Probenecid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mutual Pharmaceutical Company, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 28,
      "start_date": "2007-09",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2009-12-09",
      "last_synced_at": "2026-10-19T15:50:06.161Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01021020"
    },
    {
      "nct_id": "NCT07778524",
      "title": "Alpelisib Challenge Test (ACT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Resistance",
        "Type 2 Diabetes",
        "Obesity & Overweight",
        "Healthy Adult Participants"
      ],
      "interventions": [
        {
          "name": "Alpelisib 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Hyperglycemic clamp",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2026-09-02",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-19T15:50:06.161Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07778524"
    },
    {
      "nct_id": "NCT06319170",
      "title": "Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia, Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Olanzapine Extended Release",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine Immediate Release",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 106,
      "start_date": "2024-03-28",
      "completion_date": "2025-01-20",
      "has_results": true,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-10-19T15:50:06.161Z",
      "location_count": 5,
      "location_summary": "Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06319170"
    },
    {
      "nct_id": "NCT07581860",
      "title": "Growth Hormone Resistance of Beta-cells",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy",
        "Obesity & Overweight",
        "Impaired Fasting Glucose (IFG)",
        "Impaired Glucose Tolerance (Prediabetes)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 10,
      "start_date": "2026-08-01",
      "completion_date": "2030-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-19T15:50:06.161Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07581860"
    },
    {
      "nct_id": "NCT03687827",
      "title": "A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin degludec",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 498,
      "start_date": "2018-10-02",
      "completion_date": "2019-12-27",
      "has_results": true,
      "last_update_posted_date": "2021-01-12",
      "last_synced_at": "2026-10-19T15:50:06.161Z",
      "location_count": 34,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03687827"
    },
    {
      "nct_id": "NCT03108924",
      "title": "The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Insufficiency"
      ],
      "interventions": [
        {
          "name": "Gefapixant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 24,
      "start_date": "2017-04-14",
      "completion_date": "2017-09-13",
      "has_results": true,
      "last_update_posted_date": "2022-07-27",
      "last_synced_at": "2026-10-19T15:50:06.161Z",
      "location_count": 2,
      "location_summary": "Hialeah, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03108924"
    }
  ]
}